GigaGen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-03-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gigagen.com
Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- GigaGen, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT07024641
- Locations
- 🇺🇸
Grifols Investigative site, Richmond, Virginia, United States
🇺🇸Grifols Investigative Site, Iowa City, Iowa, United States
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid Tumor Malignancies
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- GigaGen, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06258304
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- GigaGen, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04883138
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
News
No news found